Valina L Dawson

This inventor holds 11 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Johns Hopkins University, Valted, LLC, The United States of America. Active years: 1993-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Valina L Dawson. Retrieved from https://idiyas.com/inventor/valina-l-dawson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 11)

% Patents Active = 81.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 111(Granted Patents)

Company Filing History:

6 out of 3,798

Johns Hopkins University

The United States of America

patents

4. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12276657 - Detection of PAR in the CSF of patients with Parkinson's disease (2025-04-14),

2. 12233109 - Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions (2025-02-25),

3. 11123405 - Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions (2021-09-21),

4. 9623039 - Treatment and prevention of pathological conditions using iduna related techniques and compositions (2017-04-18),

5. 9274128 - Transcriptional repression leading to parkinson's disease (2016-03-01),

6. 8921042 - Transcriptional repression leading to Parkinson's disease (2014-12-30),

7. 8603994 - Transcriptional repression leading to Parkinson's disease (2013-12-10),

8. 6362160 - Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases (2002-03-26),

9. 6358975 - Method of using selective parp inhibitors to prevent or treat neurotoxicity (2002-03-19),

10. 5587384 - Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA (1996-12-24),

11. 5266594 - Inhibitors of nitric oxide synthase and use thereof to prevent glutamate (1993-11-30),

Title: Valina L. Dawson: Innovator in Neurodegenerative Disease Research

Introduction

Valina L. Dawson is a prominent inventor based in Baltimore, MD, known for her significant contributions to the field of neurodegenerative diseases. With a total of 11 patents to her name, she has made remarkable strides in developing diagnostic and therapeutic methods for conditions such as Parkinson's disease.

Latest Patents

One of her latest patents focuses on the detection of poly(ADP-ribose) (PAR) in the cerebrospinal fluid (CSF) of patients with Parkinson's disease. This innovative method aims to provide a routine laboratory test for diagnosing, assessing, and monitoring patients suffering from Parkinson's disease. The invention correlates PAR concentration in the CSF with the medical condition of patients, establishing PAR as a potential biomarker for the disease. Another significant patent involves the use of long-acting GLP-1 receptor agonists as a therapy for neurological and neurodegenerative conditions. This invention highlights the neuroprotective and disease-modifying effects of these agonists on the central nervous system.

Career Highlights

Valina L. Dawson has worked with esteemed institutions, including The Johns Hopkins University and Valted, LLC. Her work has been instrumental in advancing the understanding and treatment of neurodegenerative diseases, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Valina has collaborated with notable individuals such as Ted M. Dawson and Han Seok Ko, contributing to a rich exchange of ideas and innovations in her field.

Conclusion

Valina L. Dawson's innovative work in neurodegenerative disease research has led to significant advancements in diagnostics and therapies. Her contributions continue to impact the medical community and improve the lives of patients affected by these challenging conditions.

Profile summary based on public USPTO records.